BiotechTube

tibolone + raloxifen

ApprovedCompleted
0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Osteopenia

Conditions

Osteopenia

Trial Timeline

Jul 31, 2000 → Feb 15, 2005

NCT ID
NCT00431431

About tibolone + raloxifen

tibolone + raloxifen is a approved stage product being developed by Organon for Osteopenia. The current trial status is completed. This product is registered under clinical trial identifier NCT00431431. Target conditions include Osteopenia.

What happened to similar drugs?

4 of 9 similar drugs in Osteopenia were approved

Approved (4) Terminated (0) Active (5)
✅Teriparatide + Zoledronic AcidEli LillyApproved
✅alendronate sodiumMerckApproved
🔄zoledronic acidNovartisPhase 3
✅zoledronic acid vs pamidronateNovartisApproved
🔄Zoledronic Acid + PlaceboNovartisPhase 3
✅Placebo + ibandronate [Bonviva/Boniva]RocheApproved
🔄ibandronate [Bonviva/Boniva] + PlaceboRochePhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00431431ApprovedCompleted

Competing Products

18 competing products in Osteopenia

See all competitors
ProductCompanyStageHype Score
Teriparatide + Zoledronic AcidEli LillyApproved
43
alendronate sodiumMerckApproved
43
zoledronic acidNovartisPhase 3
40
zoledronic acid vs pamidronateNovartisApproved
43
Zoledronic Acid + PlaceboNovartisPhase 3
40
BPS804 20mg/Kg + Placebo to 20mg/Kg BPS804NovartisPhase 2
35
Placebo + ibandronate [Bonviva/Boniva]RocheApproved
43
ibandronate [Bonviva/Boniva] + PlaceboRochePhase 3
40
Romosozumab + PlaceboAmgenPhase 1
29
Placebo + AMG 167AmgenPhase 1
29
AMG 167 + PlaceboAmgenPhase 1
29
Romosozumab + PlaceboAmgenPhase 1
29
DenosumabAmgenPhase 3
40
Romosozumab + PlaceboAmgenPhase 1
29
Dasatinib 100 Mg Oral TabletNovo NordiskPhase 2
39
RN564PfizerPhase 1
29
risedronate + alendronateSanofiPhase 1
29
Menostar (Estradiol, BAY86-5435) + RaloxifeneBayerPhase 3
37